KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Change in Cash: 2009-2025

Historic Change in Cash for Halozyme Therapeutics (HALO) over the last 15 years, with Sep 2025 value amounting to $357.8 million.

  • Halozyme Therapeutics' Change in Cash rose 1166.61% to $357.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $265.3 million, marking a year-over-year increase of 321.29%. This contributed to the annual value of -$2.5 million for FY2024, which is 97.83% up from last year.
  • According to the latest figures from Q3 2025, Halozyme Therapeutics' Change in Cash is $357.8 million, which was up 412.58% from -$114.5 million recorded in Q2 2025.
  • Over the past 5 years, Halozyme Therapeutics' Change in Cash peaked at $357.8 million during Q3 2025, and registered a low of -$373.0 million during Q4 2021.
  • In the last 3 years, Halozyme Therapeutics' Change in Cash had a median value of $23.2 million in 2024 and averaged $16.8 million.
  • In the last 5 years, Halozyme Therapeutics' Change in Cash surged by 2,390.17% in 2021 and then crashed by 15,489.59% in 2023.
  • Over the past 5 years, Halozyme Therapeutics' Change in Cash (Quarterly) stood at -$373.0 million in 2021, then surged by 123.34% to $87.0 million in 2022, then crashed by 279.07% to -$155.9 million in 2023, then surged by 75.32% to -$38.5 million in 2024, then surged by 1,166.61% to $357.8 million in 2025.
  • Its Change in Cash stands at $357.8 million for Q3 2025, versus -$114.5 million for Q2 2025 and $60.5 million for Q1 2025.